2023 Was a tricky 12 months for the biopharma sector, with several organizations downsizing and restructuring their workforces to remain afloat. There are signs of recovery, as mergers and acquisitions picked up across the pharmaceutical and lifestyle sciences market while in the latter Component of 2023 and possess ongoing their https://sites.google.com/view/bio-sites/blog